The available data is heterogeneous and no clear trend has emerged, although one can be relatively confident in saying that—at least for the assays that are commercially available—anti-MPO/PR3 autoantibodies do not specifically identify SLE patients, nor do they track with specific disease manifestations. The gene discussed is MPO; the disease is systemic lupus erythematosus.